|
2025 Conference Publication Spatial transcriptomics reveals molecular determinants of mortality in thin melanomaZhou, C., Tan, S.X., Kao, Y., Claeson, M., Brown, S., Lambie, D., Whiteman, D.C., Pandeya, N., Olsen, C.M., Barbour, A., MacGregor, S., Soyer, H.P., Stark, M.S., Hayward, N., Smithers, B.M., Nguyen, Q. and Khosrotehrani, K. (2025). Spatial transcriptomics reveals molecular determinants of mortality in thin melanoma. Society for Investigative Dermatology (SID) 2025 Meeting, San Diego, CA United States, 7-10 May 2025. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jid.2025.06.109 |
|
2025 Conference Publication Identifying genetic drivers of oesophageal adenocarcinomaAoude, Lauren G., Brosda, Sandra, Wong, Ho Yi, Koufariotis, Lambros, Pearson, John V., Waddell, Nicola and Barbour, Andrew P. (2025). Identifying genetic drivers of oesophageal adenocarcinoma. 21st ISDE World Congress for Esophageal Diseases, Brisbane, QLD Australia, 18-20 September 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/dote/doaf061.354 |
|
2025 Conference Publication Spatial transcriptomics profiling of the tumour microenvironment of esophageal adenocarcinomaBelle, Clemence, Brosda, Sandra, Bonazzi, Vanessa, Kao, Yung-Ching, Brown, Ian, Aoude, Lauren, Stark, Mitchell, Patel, Kalpana, AGITG AGITG DOCTOR Investigators, Atkinson, Victoria and Barbour, Andrew (2025). Spatial transcriptomics profiling of the tumour microenvironment of esophageal adenocarcinoma. 21st ISDE World Congress for Esophageal Diseases, Brisbane, QLD Australia, 18-20 September 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/dote/doaf061.357 |
|
2025 Conference Publication Development of novel immunotherapy-based therapies in oesophageal adenocarcinoma by harnessing tumour neoantigensLonie, James, Brosda, Sandra, Addala, Venkateswar, Bonazzi, Vanessa, Aoude, Lauren, Zeng, Bijun, Waddell, Nicola, Dolcetti, Riccardo and Barbour, Andrew (2025). Development of novel immunotherapy-based therapies in oesophageal adenocarcinoma by harnessing tumour neoantigens. 21st ISDE World Congress for Esophageal Diseases, Brisbane, QLD Australia, 18-20 September 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/dote/doaf061.314 |
|
2025 Conference Publication Unravelling melanoma brain metastasis tumor microenvironment characteristics using spatial transcriptomicsBelle, Clemence J., Brosda, Sandra, Bonazzi, Vanessa F., Bulteau, Victor, Stuart, Thomas, Xiong, Zherui, Lambie, Duncan, Johansson, Peter A., Aoude, Lauren G., Patel, Kalpana, Stehbens, Samantha J., Stark, Mitchell S., Haass, Nikolas K., Xu, Wen, Pinkham, Mark B., Foote, Matthew C., Olson, Sarah, Atkinson, Victoria, Kulasinghe, Arutha, Nguyen, Quan H. and Barbour, Andrew (2025). Unravelling melanoma brain metastasis tumor microenvironment characteristics using spatial transcriptomics. AACR Annual Meeting 2025, Chicago, IL United States, 25-30 April 2025. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2025-5076 |
|
2024 Conference Publication Alterations In Local Oesophageal Microbiota And Outcomes After Oesophagectomy For Oesophago-gastric Cancer: A Pilot StudyStokes, Matthew, (Frank) Yu, Zirong, Schlebusch, Sanmarie, Jennison, Amy, Graham, Rikki, Cooper, Caroline, Smithers, B. Mark, Barbour, Andrew, Thomson, Iain and Frankel, Adam (2024). Alterations In Local Oesophageal Microbiota And Outcomes After Oesophagectomy For Oesophago-gastric Cancer: A Pilot Study. 20th ISDE World Congress for Esophageal Diseases, Edinburgh, United Kingdom, 22 - 24 September 2024. Cary, NC United States: Oxford University Press. doi: 10.1093/dote/doae057.006 |
|
2024 Conference Publication Unsupervised clustering of PET/CT imaging features in stage III/IV melanomaVashistha, Rajat, Moradi, Hamed, Brosda, Sandra, Aoude, Lauren, Vegh, Viktor and Barbour, Andrew (2024). Unsupervised clustering of PET/CT imaging features in stage III/IV melanoma. Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Toronto, ON, Canada, 8-11 June 2024. Reston, VA, United States: Society of Nuclear Medicine. |
|
2022 Conference Publication Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinomaAoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357 |
|
2020 Conference Publication Tracking genomic and transcriptomic features of oesophageal adenocarcinoma for improving patients outcomeNaeini, Marjan, Newell, Felicity, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Koufariotis, Lambros T., Johnson, Rebecca, Addala, Venkateswar, Kondrashova, Olga, Holmes, Oliver, Leonard, Conrad, Wood, Scott, Xu, Christina, Nones, Katia, Pearson, John V., Smithers, Mark, Watson, David, Simes, John, Price, Tim, Gebski, Val, Barbour, Andrew P. and Waddell, Nic (2020). Tracking genomic and transcriptomic features of oesophageal adenocarcinoma for improving patients outcome. HOBOKEN: WILEY. |
|
2018 Conference Publication Neoadjuvant therapy for esophageal adenocarcinoma: a propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapyBarbour, A. P., Brosda, S., Wijnhoven, B., van Hootgem, S., Lanschot, J. J. B., Barbour, S., Lagarde, S., Krause, L., Pryor, D., Thomas, J., Walpole, E. T., van der Gaast, A. and Smithers, M. (2018). Neoadjuvant therapy for esophageal adenocarcinoma: a propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy. 43rd ESMO Congress (ESMO), Munich, Germany, 19-23 October 2018. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdy282.015 |
|
2017 Conference Publication Long-term health-related quality of life following esophagectomy: A nonrandomized comparison of thoracoscopically assisted and open surgeryBarbour, Andrew P., McCormack, Orla M. , Baker, Peter J., Hirst, Jodi, Krause, Lutz, Brosda, Sandra, Thomas, Janine M., Blazeby, Jane M., Thomson, Iain G., Gotley, David C. and Smithers, Bernard M. (2017). Long-term health-related quality of life following esophagectomy: A nonrandomized comparison of thoracoscopically assisted and open surgery. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1097/SLA.0000000000001899 |
|
2016 Conference Publication An AGITG trial - A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel plus /-radio Therapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinomaBarbour, A., Walpole, E., Mai, G. T., Chan, H., Barnes, E., Watson, D., Ackland, S., Wills, V., Martin, J., Burge, M., Karapetis, C., Shannon, J., Nott, L., Gebski, V., Wilson, K., Thomas, J., Lampe, G., Zalcberg, J., Simes, J. and Smithers, M. (2016). An AGITG trial - A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel plus /-radio Therapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma. 41st Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7-11 October 2016. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdw371.02 |
|
2016 Conference Publication Prognostic value of nomograms incorporating biomarkers vs. sentinel node status in patients with stage IB and II melanomaRowe, C., Tang, F., Hughes, M. C., Rodero, M., Malt, M., Lambie, D., Barbour, A., Hayward, N., Smithers, B. M., Green, A. and Khosrotehrani, K. (2016). Prognostic value of nomograms incorporating biomarkers vs. sentinel node status in patients with stage IB and II melanoma. Australasian College of Dermatologists 49th Annual Scientific Meeting, Perth, Australia, 14–17 May, 2016. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/ajd.12480 |
|
2014 Conference Publication Discovery and validation of novel serum glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinomaShah, Alok K., Chen, David, Le Cao, Kim-Anh, Choi, Eunju, Nancarrow, Derek, Whiteman, David, Saunders, Nicholas A., Barbour, Andrew P. and Hill, Michelle M. (2014). Discovery and validation of novel serum glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinoma. 105th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, CA United States, 05-09 April 2014. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.AM2014-2492 |
|
2014 Conference Publication Oesophageal adenocarcinoma genomicsBarbour, Andrew (2014). Oesophageal adenocarcinoma genomics. Sydney Cancer Conference, The University of Sydney, Australia, 26 November 2014. West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12282 |
|
2012 Conference Publication Gene expression analysis of EAC in association with PET response.Wayte, Nicola, Nancarrow, Derek, Walpole, Euan Thomas, Lampe, Guy, Gotley, David, Smithers, Bernard Mark and Barbour, Andrew (2012). Gene expression analysis of EAC in association with PET response.. ASCO GI Symposium, San Diego, CA United States, 24 January 2012. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2012.30.4_suppl.50 |
|
2012 Conference Publication DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junctionBarbour, Andrew, Smithers, Bernard Mark, Burmeister, Bryan, Zalcberg, John Raymond, Spry, Nigel, Smith, Garrett, Wilson, Kate, Roff, Kate, Yip, Sonia and Walpole, Euan Thomas (2012). DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Il United States, 01-06 June 2012. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2011 Conference Publication Genomic and genetic characterization of human Cholangiocarcinoma identifies treatment options for tyrosine kinase inhibitorsAndersen, Jesper B., Spee, Bart, Blechacz, Boris, Avital, Itzhak, Komuta, Mina, Barbour, Andrew, Roskams, Tania, Roberts, Lewis R., Factor, Valentina M. and Thorgeirsson, Snorri S. (2011). Genomic and genetic characterization of human Cholangiocarcinoma identifies treatment options for tyrosine kinase inhibitors. 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, United States, 04-08 November 2011. |
|
2008 Conference Publication Minimally invasive esophagectomy for esophageal cancer: Analysis of recurrence patterns and prognostic factors of recurrenceBarbour, A., Thompson, I., Gotley, D. C., Jones, M., Thomas, J., Martin, I. and Smithers, M. B. (2008). Minimally invasive esophagectomy for esophageal cancer: Analysis of recurrence patterns and prognostic factors of recurrence. Clinical Oncological Society of Australia and the International Association of Cancer Registries Joint Scientific Meeting, held in conjunction with the Australian and New Zealand Gastro-Oesophageal Surgery Association, Sydney, Australia, 18–20 November 2008. United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/j.1743-7563.2008.00201_2.x |
|
2008 Conference Publication A randomised phase II trial comparing pre-operative chemotherapy with pre-operative chemoradiation therapy for localized carcinoma of the oesophagusBurmeister, B. H., Smithers, B. M., Thomas, J., Burmeister, E., Walpole, E., Harvey, J., Thomson, D., Barbour, A. and Gotley D. (2008). A randomised phase II trial comparing pre-operative chemotherapy with pre-operative chemoradiation therapy for localized carcinoma of the oesophagus. Clinical Oncological Society of Australia and the International Association of Cancer Registries Joint Scientific Meeting, held in conjunction with the Australian and New Zealand Gastro-Oesophageal Surgery Association, Sydney, Australia, 18-20 November 2008. United Kingdom: Wiley-Blackwell. doi: 10.1111/j.1743-7563.2008.00201_1.x |
